P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION. (23rd June 2022) - Beauvais, D.; Sourisseau, M.; Béhal, H.; Alfandari, S.; Simon, N.; Faure, E.; Yakoub-Agha, I.